MedTrace Logo

Malaria Molecular Surveillance in Mozambique (Phase 2)

NCT06529237 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 18750

Last updated 2024-08-26

No results posted yet for this study

Summary

Mozambique is among the ten countries with the highest burden of malaria worldwide, with an estimated 10.3 million cases in 2021. Malaria transmission is highly heterogeneous across the country, with high burden in the north and very low burden in the south, therefore requiring different strategies for effective control and potential elimination. The GenMoz study (NCT05306067, March 2021-Feb 2024) operationalized a functional malaria molecular surveillance (MMS) system to generate reliable and reproducible temporal genomic data to monitor the effectiveness of rapid diagnostic tests and antimalarials, as well as to continuously characterize transmission levels and sources. The National Malaria Control Program (NMCP) is starting a new strategic cycle (2023-2030) with a plan that includes genomic surveillance for guiding programmatic decisions on six key antimalarial tools : 1. Malaria diagnostics using rapid diagnostic tests (RDTs) based on histidine-rich protein 2 (HRP2); 2. Treatment with artemisinin-based combination therapies (ACTs), including diversification schemes to reduce emergence of resistance; 3. Chemoprevention for pregnant women and children; 4. R21/Matrix-M vaccine rollout; 5. Individual-level interventions in very low transmission settings and 6. Vector control. In Phase 2, the investigators aim to integrate MMS into this wider surveillance framework and scale MMS in Mozambique for quality, timely and appropriate optimization of the public health benefits of the NMCP 2023-2030 strategy in both a proactive and adaptive manner, selecting the combinations of interventions that maximize the impact at the individual and community level.

Conditions

  • Malaria
  • Falciparum Malaria
  • Malaria in Pregnancy

Interventions

DIAGNOSTIC_TEST

LDH-based malaria rapid diagnostic test

Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities

DIAGNOSTIC_TEST

Malaria rapid diagnostic test

Routine malaria rapid diagnostic tests

Sponsors & Collaborators

  • Barcelona Institute for Global Health

    collaborator OTHER

  • University of California, San Francisco

    collaborator OTHER

  • National Malaria Control Program, Mozambique

    collaborator UNKNOWN

  • Centro de Investigacao em Saude de Manhica

    lead OTHER

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Mozambique

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06529237 on ClinicalTrials.gov